Slide 1: Q2 FY2023 Financial Results
Q2 FY2023 Financial Results May 2, 2023
Slide 2: Cautionary note regarding forward-looking statements
Cautionary note regarding forward-looking statements Certain of the statements contained in this presentation are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Securit
Slide 3: AmerisourceBergen is united in our responsibility to create healthier futures
AmerisourceBergen is united in our responsibility to create healthier futures. AmerisourceBergen creates unparalleled access, efficiency, and reliability for human and animal health as a leading provider of pharmaceutical distribution services and differentiated value-added solutions for upstream an
Slide 4: Overview
Overview Recent highlights Global healthcare leader Fiscal 2023 guidance • Results and increase in • Foundation of leadership • Updated fiscal 2023 full-year outlook continue in pharmaceutical guidance primarily to demonstrate the value distribution reflects stronger core of pharmaceutical-centric •
Slide 5: Q2 FY2023 financial results
Q2 FY2023 financial results Consolidated results GAAP Adjusted (non-GAAP)1 Revenue $63.5B $63.5B % Change (Year-over-Year) 9.9% 9.9% Gross profit $2.3B $2.4B % Change 2.7% 6.2% Operating expenses $1.7B $1.4B % Change 19.2% 9.4% Operating income $561M $932M % Change (28.2)% 1.7% Interest expense, net
Slide 6: Q2 FY2023 financial results: U.S. Healthcare Solutions segment
Q2 FY2023 financial results U.S. Healthcare Solutions segment Q2 FY2023 Q2 FY2022 YoY Change Revenue $56.7B $50.9B 11.3% Operating income $756M $730M 3.6% Percentages of revenue Gross profit 2.74% 2.87% Operating expenses 1.40% 1.44% Operating income 1.33% 1.43% • Revenue increase of 11.3% due to ov
Slide 7: Q2 FY2023 financial results: International Healthcare Solutions segment
Q2 FY2023 financial results International Healthcare Solutions segment Q2 FY2023 Q2 FY2022 YoY Change Revenue, as reported $6.8B $6.8B (0.2)% Revenue, constant currency1 11.9% Operating income, as reported $176M $187M (5.9)% Operating Income, constant currency1 7.3% Percentages of revenue, as report
Slide 8: Consolidated FY 2023 guidance
Consolidated FY 2023 guidance Updated guidance primarily reflects stronger core growth in U.S. Healthcare Solutions As reported Constant currency1 As reported Constant excluding currency1 COVID-19 excluding COVID contributions Revenue 6% to 8% 6% to 8% Adjusted operating income1 2% to 4% 5% to 7% 5%
Slide 9: Segment level FY 2023 guidance
Segment level FY 2023 guidance Updated guidance primarily reflects stronger core growth in U.S. Healthcare Solutions U.S. Healthcare Solutions As reported Excluding COVID-19 contributions Revenue 7% to 8% Adjusted operating income1 3% to 5% 6% to 8% International Healthcare As reported Constant As r
Slide 10: Creating differentiated value for our stakeholders
Creating differentiated value for our stakeholders Our long-term, sustainable growth is supported by investments in our people and culture and commitment to ESG Why we exist Our 5 Strategic Imperatives We are united in our responsibility to create healthier futures Our areas of focus Advance core bu
Slide 11: Advancing environmental, social, and governance initiatives to create healthier futures
Advancing environmental, social, and governance initiatives to create healthier futures around the world ENVIRONMENTAL SOCIAL Adapting to a changing climate Investing in our people and communities • Near-term Science-Based Target validated by • Launched a Global Inclusion Index to measure the Scienc
Slide 12: Appendix
AmerisourceBergen Appendix
Slide 13: GAAP to Non-GAAP Reconciliations: Three Months Ended March 31, 2023
AMERISOURCEBERGEN CORPORATION GAAP TO NON-GAAP RECONCILIATIONS (in thousands, except per share data) (unaudited) Three Months Ended March 31, 2023 Net Loss Income Attributable to Net Income Diluted Operating Operating Before Income Tax Noncontrolling Attributable Earnings Gross Profit Expenses Incom
Slide 14: GAAP to Non-GAAP Reconciliations: Three Months Ended March 31, 2022
AMERISOURCEBERGEN CORPORATION GAAP TO NON-GAAP RECONCILIATIONS (in thousands, except per share data) (unaudited) Three Months Ended March 31, 2022 Income Net Income Before Attributable to Net Income Diluted Operating Operating Income Income Tax Noncontrolling Attributable Earnings Gross Profit Expen
Slide 15: Supplemental Information Regarding Non-GAAP Financial Measures
Supplemental Information Regarding Non-GAAP Financial Measures To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses the non-GAAP financial measures described below. The non-GAAP financial measures should be viewed in
Slide 16: Supplemental Information Regarding Non-GAAP Financial Measures (Cont.)
Supplemental Information Regarding Non-GAAP Financial Measures (Cont.) • Adjusted income before income taxes: Adjusted income before income taxes is a non-GAAP financial measure that excludes the same items that are described above and excluded from adjusted operating income. In addition, the recove
Slide 17: Supplemental Information Regarding Non-GAAP Financial Measures (Cont.)
Supplemental Information Regarding Non-GAAP Financial Measures (Cont.) • Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments including gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credi
Slide 18: Contact
Contact Bennett S. Murphy Senior Vice President Head of Investor Relations and Treasury bmurphy@amerisourcebergen.com